Biotalys, Syngenta reach research milestone in bioinsecticide development
Biotalys and Syngenta report early success in developing a protein-based bioinsecticide, moving into next research phase. The collaboration targets resistance and regulatory challenges.
Key takeaways
- Biotalys and Syngenta reached a first research milestone in bioinsecticide development
- Early lab tests showed activity against an insect target
- Project will move into in vivo testing
Biotalys reported an early research milestone in its collaboration with Syngenta to develop a protein-based bioinsecticide, with initial laboratory tests showing activity against a targeted insect mechanism.
The companies are working to develop new crop protection tools using Biotalys’ AGROBODY technology, which produces bioactive proteins designed to target pests. Early in vitro results demonstrated effectiveness against a specific insect molecular target, marking the first step in the joint research program.
The project comes as growers face increasing insect resistance and tighter regulatory constraints on conventional chemistries. Protein-based biocontrols are being explored as an alternative that can offer targeted pest management while reducing environmental impact.
Carlo Boutton, interim CEO of Biotalys, said the milestone supports the potential of the company’s technology platform in insect control and reflects progress toward new modes of action that can be integrated into pest management programs.
The collaboration will now move into the next phase, where selected bioactive compounds will be tested in vivo. Syngenta will make a milestone payment to Biotalys tied to this progress, though the company said it will not materially affect its current cash runway.
Biotalys and Syngenta reported early laboratory success in developing a protein-based bioinsecticide. The project will now advance to testing in living organisms as part of ongoing research.
FAQ
Q: What did Biotalys announce?
A: It reached a first research milestone in a bioinsecticide collaboration with Syngenta.
Q: What technology is being used?
A: Biotalys’ AGROBODY protein-based platform.
Q: What were the initial results?
A: Laboratory tests showed activity against an insect molecular target.
Q: What is the next step?
A: In vivo testing of the bioactive ingredients.
Q: Why is this research important?
A: It aims to address insect resistance and environmental concerns in crop protection.
What this means
The work reflects continued interest in biological alternatives to conventional insecticides, though development remains at an early stage.